Sun Pharmaceutical Industries continues enjoying rich valuations on the bourses, thanks to its ability to consistently deliver good growth. The September quarter results were no different. The strong top line growth of 42 per cent came on the back of 16 per cent rise in domestic sales and 77 per cent jump in the US sales that together contributed four-fifths of sales.
2396
2899
358
0
16000
40000
4161
0
78
150
6999
9999
2100
4199
2697
3263
370
433
600
1200
1790
2166
7550
15099
580
790